Preventing catheter-related bacteremia with taurolidine-citrate catheter locks: A systematic review and meta-analysis

Blood Purification

Volumn 37, Issue 3, 2014, Pages 179-187

  Liu, Hongbo ^a   Liu, Hongmei ^c   Deng, Jing ^b   Chen, Lihua ^a   Yuan, Lu ^a   Wu, Yong ^a  

^a THE THIRD XIANGYA HOSPITAL OF CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Catheter related bacteremia; Heparin; Intravascular catheters; Meta analysis; Taurolidine citrate

Indexed keywords

ANTICOAGULANT AGENT; ANTIINFECTIVE AGENT; CITRIC ACID; TAURINE; TAUROLIDINE; THIADIAZINE DERIVATIVE; COTRIMOXAZOLE; HEPARIN; PSEUDOMONIC ACID;

ANALOGS AND DERIVATIVES; BACTEREMIA; CENTRAL VENOUS CATHETER; FEMALE; HUMAN; MALE; MEDLINE; META ANALYSIS; BLOOD CULTURE; CATHETER; CATHETER INFECTION; GRAM NEGATIVE INFECTION; INFECTION PREVENTION; INFORMATION RETRIEVAL; INTRAVASCULAR CATHETER; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; TAUROLIDINE CITRATE CATHETER LOCK;

ANTI-INFECTIVE AGENTS; ANTICOAGULANTS; BACTEREMIA; CITRIC ACID; FEMALE; HUMANS; MALE; PUBMED; TAURINE; THIADIAZINES; VASCULAR ACCESS DEVICES;

EID: 84899600391     PISSN: 02535068     EISSN: 14219735     Source Type: Journal    
DOI: 10.1159/000360271     Document Type: Review

References (40)

1. Castagnola E, Ginocchio F: Rescue therapy of difficult-to-treat indwelling central venous catheter-related bacteremias in cancer patients: a review for practical purposes. Expert Rev Anti Infect Ther 2013; 11:179-186.
2. Li S, Bizzarro MJ: Prevention of central line associated bloodstream infections in critical care units. Curr Opin Pediatr 2010; 23:85-90.
3. Bradshaw JH, Puntis JW: Taurolidine and catheter-related bloodstream infection: a systematic review of the literature. J Pediatr Gas-troenterol Nutr 2008; 47:179-186.
4. Opilla M: Epidemiology of bloodstream infection associated with parenteral nutrition. Am J Infect Control 2008; 36:S173.e5-e8.
5. Santarpia L, Pasanisi F, Alfonsi L, Violante G, Tiseo D, De Simone G, Contaldo F: Prevention and treatment of implanted central venous catheter (CVCH)-related sepsis: a report after six years of home parenteral nutrition (HPN). Clin Nutr 2002; 21:207-211. (Pubitemid 34846799)
6. Jurewitsch B, Jeejeebhoy KN: Taurolidine lock: The key to prevention of recurrent catheter-related bloodstream infections. Clin Nutr 2005; 24:462-465. (Pubitemid 40668434)
7. Weber DJ, Rutala WA: Central line-associated bloodstream infections: prevention and management. Infect Dis Clin North Am 2011; 25:77-102.
8. Al-Amin AH, Sarveswaran J, Wood JM, Burke DA, Donnellan CF: Efficacy of taurolidine on the prevention of catheter-related bloodstream infections in patients on home parenteral nutrition. J Vasc Access 2013; 14: 379-382.
9. Rabe C, Gramann T, Sons X, Berna M, Gon-zalez-Carmona MA, Klehr HU, Sauerbruch T, Caselmann WH: Keeping central venous lines open: a prospective comparison of heparin, vitamin C and sodium chloride sealing solutions in medical patients. Intensive Care Med 2002; 28:1172-1176. (Pubitemid 34985247)
10. Simon A, Ammann RA, Wiszniewsky G, Bode U, Fleischhack G, Besuden MM: Tauro-lidine-citrate lock solution (TauroLock) significantly reduces CVAD-associated gram-positive infections in pediatric cancer patients. BMC Infect Dis 2008; 8:102.
11. Solomon LR, Cheesbrough JS, Bhargava R, Mitsides N, Heap M, Green G, Diggle P: Observational study of need for thrombolytic therapy and incidence of bacteremia using taurolidine-citrate-heparin, taurolidine-citrate and heparin catheter locks in patients treated with hemodi-alysis. Semin Dial 2011; 25: 233-238.
12. Mandolfo S: Central venous catheter lock to prevent thrombosis and bacterial infection (in Italian). G Ital Nefrol 2012; 29:301-307.
13. Labriola L, Crott R, Jadoul M: Preventing hae-modialysis catheter-related bacteraemia with an antimicrobial lock solution: a meta-analy-sis of prospective randomized trials. Nephrol Dial Transplant 2008; 23:1666-1672. (Pubitemid 351767750)
14. Silva TN, Mendes ML, Abrao JM, Caramori JT, Ponce D: Successful prevention of tunneled central catheter infection by antibiotic lock therapy using cefazolin and gentamicin. Int Urol Nephrol 2013; 45:1405-1413.
15. Weber JM, Sheridan RL, Fagan S, Ryan CM, Pasternack MS, Tompkins RG: Incidence of catheter-associated bloodstream infection after introduction of minocycline and rifampin antimicrobial-coated catheters in a pediatric burn population. J Burn Care Res;33: 539-543.
16. Landry DL, Braden GL, Gobeille SL, Haessler SD, Vaidya CK, Sweet SJ: Emergence of gen-tamicin-resistant bacteremia in hemodialysis patients receiving gentamicin lock catheter prophylaxis. Clin J Am Soc Nephrol 2010; 5: 1799-1804.
17. Droste JC, Jeraj HA, MacDonald A, Far-rington K: Stability and in vitro efficacy of antibiotic-heparin lock solutions potentially useful for treatment of central venous catheter-related sepsis. J Antimicrob Chemother 2003; 51:849-855. (Pubitemid 36503418)
18. Fratino G, Molinari AC, Parodi S, Longo S, Saracco P, Castagnola E, Haupt R: Central venous catheter-related complications in children with oncological/hematological diseases: an observational study of 418 devices. Ann Oncol 2005; 16:648-654. (Pubitemid 40613333)
19. Traub WH, Leonhard B, Bauer D: Tauro-lidine: In vitro activity against multiple-antibiotic-resistant, nosocomially significant clinical isolates of Staphylococcus aureus, En-terococcus faecium, and diverse Enterobacte-riaceae. Chemotherapy 1993; 39:322-330. (Pubitemid 23238716)
20. Handrup MM, Fuursted K, Funch P, Moller JK, Schroder H: Biofilm formation in long-term central venous catheters in children with cancer: a randomized controlled open-labelled trial of taurolidine versus heparin. APMIS 2012; 120:794-801.
21. Shah CB, Mittelman MW, Costerton JW, Pa-renteau S, Pelak M, Arsenault R, Mermel LA: Antimicrobial activity of a novel catheter lock solution. Antimicrob Agents Chemother 2002; 46:1674-1679. (Pubitemid 34535182)
22. Willatts SM, Radford S, Leitermann M: Effect of the antiendotoxic agent, taurolidine, in the treatment of sepsis syndrome: a placebo-controlled, double-blind trial. Crit Care Med 1995; 23:1033-1039.
23. Filiopoulos V, Hadjiyannakos D, Koutis I, Trompouki S, Micha T, Lazarou D, Vlasso-poulos D: Approaches to prolong the use of uncuffed hemodialysis catheters: results of a randomized trial. Am J Nephrol 2011; 33:260-268.
24. Geron R, Tanchilevski O, Kristal B: Catheter lock solution-taurolock for prevention of catheter-related bacteremia in hemodialysis patients (in Hebrew). Harefuah 2006; 145: 881-884, 943.
25. DerSimonian R, Kacker R: Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials 2007; 28:105-114. (Pubitemid 44937874)
26. Higgins J, Thompson S, Deeks J, Altman D: Statistical heterogeneity in systematic reviews of clinical trials: a critical appraisal of guidelines and practice. J Health Serv Res Policy 2002; 7:51-61. (Pubitemid 34041777)
27. Betjes MG, van Agteren M: Prevention of dialysis catheter-related sepsis with a citrate-taurolidine-containing lock solution. Nephrol Dial Transplant 2004; 19:1546-1551. (Pubitemid 38786749)
28. Dumichen MJ, Seeger K, Lode HN, Kuhl JS, Ebell W, Degenhardt P, Singer M, Geffers C, Querfeld U: Randomized controlled trial of taurolidine citrate versus heparin as catheter lock solution in paediatric patients with hae-matological malignancies. J Hosp Infect 2012; 80:304-309.
29. Solomon LR, Cheesbrough JS, Ebah L, Al-Sayed T, Heap M, Millband N, Waterhouse D, Mitra S, Curry A, Saxena R, Bhat R, Schulz M, Diggle P: A randomized double-blind controlled trial of taurolidine-citrate catheter locks for the prevention of bacteremia in patients treated with hemodialysis. Am J Kidney Dis 2010; 55:1060-1068.
30. Taylor C, Cahill J, Gerrish M, Little J: A new haemodialysis catheter-locking agent reduces infections in haemodialysis patients. J Ren Care 2008; 34:116-120.
31. O'Grady NP, Alexander M, Dellinger EP, Gerberding JL, Heard SO, Maki DG, Masur H, McCormick RD, Mermel LA, Pearson ML, Raad II, Randolph A, Weinstein RA: Guidelines for the prevention of intravascular catheter-related infections. Centers for disease control and prevention. MMWR Recomm Rep 2002; 51:1-29.
32. Rello J, Ochagavia A, Sabanes E, Roque M, Mariscal D, Reynaga E, Valles J: Evaluation of outcome of intravenous catheter-related infections in critically ill patients. Am J Respir Crit Care Med 2000; 162:1027-1030.
33. Dimick JB, Pelz RK, Consunji R, Swoboda SM, Hendrix CW, Lipsett PA: Increased resource use associated with catheter-related bloodstream infection in the surgical intensive care unit. Arch Surg 2001; 136:229-234. (Pubitemid 32143849)
34. Singhai M, Malik A, Shahid M, Malik MA, Goyal R: A study on device-related infections with special reference to biofilm production and antibiotic resistance. J Glob Infect Dis 2013; 4:193-198.
35. Donlan RM: Biofilm formation: A clinically relevant microbiological process. Clin Infect Dis 2001; 33:1387-1392. (Pubitemid 32955193)
36. Ebert T, Smith S, Pancari G, Wu X, Zorman J, Clark D, Cook J, Burns C, Antonello JM, Cope L, Nagy E, Meinke A, McNeely T: Development of a rat central venous catheter model for evaluation of vaccines to prevent staphy-lococcus epidermidis and staphylococcus au-reus early biofilms. Hum Vaccin 2011; 7:630-638.
37. Zwiech R, Adelt M, Chrul S: A taurolidine-citrate-heparin lock solution effectively eradicates pathogens from the catheter biofilm in hemodialysis patients. Am J Ther 2013, Epub ahead of print.
38. Torres-Viera C, Thauvin-Eliopoulos C, Souli M, DeGirolami P, Farris MG, Wennersten CB, Sofia RD, Eliopoulos GM: Activities of taurolidine in vitro and in experimental en-terococcal endocarditis. Antimicrob Agents Chemother 2000; 44:1720-1724. (Pubitemid 30340825)
39. Raad I: Intravascular-catheter-related infections. Lancet 1998; 351:893-898. (Pubitemid 28121188)
40. Cheesbrough JS, Finch RG, Burden RP: A prospective study of the mechanisms of infection associated with hemodialysis catheters. J Infect Dis 1986; 154:579-589. (Pubitemid 16032404)